Bristol-Myers Squibb Co (BMY)
71.21
+0.68 (+0.96%)
USD |
NYSE |
Oct 04, 16:00
71.08
-0.13 (-0.18%)
Pre-Market: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 152.05B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 23.66% |
| Valuation | |
| PE Ratio | 23.66 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.314 |
| Price to Book Value | 4.664 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.54 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.290 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 39.24% |
News
Headline
Wire
Time (ET)
SA Breaking News
10/04 12:50
Yahoo
10/04 10:21
MT Newswires
10/04 10:20
SA Breaking News
10/04 09:00
MT Newswires
10/04 07:49
Yahoo
10/04 07:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 10/26/2022 | -- | Results | Q3 2022 | -- | 1.84 | -- | |
| 10/26/2022 | 08:00 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 07/27/2022 | 08:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 07/27/2022 | -- | Results | Q2 2022 | 1.93 | 1.80 | 7.27% | |
| 04/29/2022 | -- | Results | Q1 2022 | 1.96 | 1.89 | 3.48% | |
| 04/29/2022 | 08:00 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 02/04/2022 | -- | Results | Q4 2021 | 1.83 | 1.80 | 1.66% | |
| 02/04/2022 | 08:00 EST | Earnings Call | Q4 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power. |
| URL | https://www.bms.com |
| Investor Relations URL | https://www.bms.com/investors.html |
| HQ State/Province | New York |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Equity Style | Large Cap/Value |
| Next Earnings Release | Oct. 26, 2022 |
| Last Earnings Release | Jul. 27, 2022 |
| Next Ex-Dividend Date | Oct. 06, 2022 |
| Last Ex-Dividend Date | Jun. 30, 2022 |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | 2.11 |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 2.017 |
| Yield to Sector | 1.606 |
| Yield to Industry | 0.8014 |
| Last Dividend Amt. | 0.54 |
| Dividend Frequency | Quarterly |
| Last Ex-Dividend Date | Jun. 30, 2022 |
| Yield (TTM) | 2.96% |
| Forward Yield | 3.03% |
| Payout Ratio | 68.37% |
| Cash Payout Ratio | 31.68% |
| Consistent Payer (5Y) |
|
| Consistent Growth (5Y) |
|
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of October 04, 2022.
Fundamentals
| Revenue (TTM) | 47.14B |
| Total Expenses (TTM) | 37.83B |
| Net Income (TTM) | 6.617B |
| Total Assets (Quarterly) | 100.36B |
| Total Liabilities (Quarterly) | 67.70B |
| Shareholders Equity (Quarterly) | 32.60B |
| Cash from Operations (TTM) | 15.40B |
| Cash from Investing (TTM) | -769.00M |
| Cash from Financing (TTM) | -14.92B |
Ratings
Profile
Edit
| Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power. |
| URL | https://www.bms.com |
| Investor Relations URL | https://www.bms.com/investors.html |
| HQ State/Province | New York |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Equity Style | Large Cap/Value |
| Next Earnings Release | Oct. 26, 2022 |
| Last Earnings Release | Jul. 27, 2022 |
| Next Ex-Dividend Date | Oct. 06, 2022 |
| Last Ex-Dividend Date | Jun. 30, 2022 |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| VGHCX | 1.526B USD | 3.36% |
| HDV | 359.02M USD | 3.10% |
| VHT | 487.25M USD | 2.62% |
| OIEQX | 1.143B USD | 2.42% |
| VPMCX | 921.67M USD | 1.54% |
| CMLFX | 1.192B USD | 1.45% |
| VDADX | 912.13M USD | 1.24% |
| VIG | 912.13M USD | 1.24% |
| VYM | 609.73M USD | 1.05% |
| IWD | 437.40M USD | 0.91% |
| VIVAX | 1.256B USD | 0.87% |
| VTV | 1.256B USD | 0.87% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| BMY Tweets |